Adverse transverse-tubule remodeling in a rat model of heart failure is attenuated with low-dose triiodothyronine treatment

Table 2 Isolated cardiomyocyte contractile measurements

		Sham	MI + Veh	MI + T3
Maximum Shortening Velocity (μm/s)		3.513 ± 0.808	3.125 ± 0.726	3.703 ± 1.213
Maximum Relengthening Velocity (μm/s)		2.299 ± 0.837	1.593 ± 0.325	2.984 ± 1.410#
Time at Maximum Relengthening Velocity (s)		0.248 ± 0.048	0.314 ± 0.019*	0.233 ± 0.037#
Peak Height as Percent of Baseline		11.17 ± 1.97	11.70 ± 1.68	12.11 ± 2.96
Time at % from Baseline to Peak Shortening (s)
	50%	0.049 ± 0.006	0.053 ± 0.005	0.054 ± 0.009
	90%	0.109 ± 0.014	0.130 ± 0.006	0.105 ± 0.020#
Time at Peak Shortening (s)		0.165 ± 0.024	0.197 ± 0.011*	0.161 ± 0.021#
Time at % from Peak Shortening to Full Relengthening (s)
	50%	0.258 ± 0.050	0.326 ± 0.018*	0.261 ± 0.071#
	90%	0.353 ± 0.071	0.443 ± 0.024*	0.324 ± 0.071#
Tau (exponential decay time constant) (s)		0.048 ± 0.019	0.067 ± 0.008	0.045 ± 0.021#
Area Under Curve of Relengthening Phase		0.021 ± 0.006	0.029 ± 0.004*	0.020 ± 0.005#

Values are mean ± SD. MI, myocardial infarction; Veh, vehicle; T3, triiodothyronine. Tau is exponential decay time constant of the sarcomere relengthening phase. Sham, n = 7; MI + Veh, n = 8, MI + T3, n = 8. One-way ANOVA, multiple group comparisons using Tukey’s analysis. *p < 0.05 vs Sham, #p < 0.05 vs MI + Veh

ISSN: 1528-3658